Insider Selling: Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Insider Sells 1,629 Shares of Stock

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Get Free Report) insider Jeffrey Dierks sold 1,629 shares of the company's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $38.02, for a total transaction of $61,934.58. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Jeffrey Dierks also recently made the following trade(s):

• On Friday, January 24th, Jeffrey Dierks sold 13,125 shares of Harmony Biosciences stock. The shares were sold at an average price of $37.31, for a total value of $489,693.75.
• On Tuesday, January 21st, Jeffrey Dierks sold 1,123 shares of Harmony Biosciences stock. The stock was sold at an average price of $40.00, for a total value of $44,920.00.
• On Wednesday, January 15th, Jeffrey Dierks sold 10,507 shares of Harmony Biosciences stock. The stock was sold at an average price of $37.01, for a total value of $388,864.07.

Harmony Biosciences Stock Down 2.2 %

HRMY stock traded down $0.87 on Friday, reaching $38.67. 274,698 shares of the company traded hands, compared to its average volume of 549,018. The firm has a fifty day simple moving average of $35.20 and a 200-day simple moving average of $35.22. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.24 and a quick ratio of 3.20. Harmony Biosciences Holdings, Inc. has a one year low of $28.14 and a one year high of $41.61. The company has a market cap of $2.21 billion, a P/E ratio of 18.33, a price-to-earnings-growth ratio of 0.51 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $186.00 million during the quarter, compared to analyst estimates of $184.07 million. During the same quarter last year, the business posted $0.63 earnings per share. The business's quarterly revenue was up 16.0% compared to the same quarter last year. Research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on HRMY shares. Mizuho boosted their price objective on shares of Harmony Biosciences from $42.00 to $52.00 and gave the stock an "outperform" rating in a research note on Thursday, October 10th. Needham & Company LLC reiterated a "buy" rating and set a $52.00 price target on shares of Harmony Biosciences in a report on Monday, January 13th. Raymond James reaffirmed an "outperform" rating and set a $40.00 price target on shares of Harmony Biosciences in a research note on Thursday, October 10th. Cantor Fitzgerald upped their price objective on shares of Harmony Biosciences from $51.00 to $58.00 and gave the company an "overweight" rating in a research note on Wednesday, October 30th. Finally, Oppenheimer reiterated an "outperform" rating and issued a $59.00 price objective (up previously from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, Harmony Biosciences has a consensus rating of "Buy" and a consensus price target of $55.00.

Institutional Trading of Harmony Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Principal Financial Group Inc. raised its stake in Harmony Biosciences by 28.4% in the fourth quarter. Principal Financial Group Inc. now owns 208,663 shares of the company's stock worth $7,180,000 after buying an additional 46,194 shares in the last quarter. Rhumbline Advisers increased its stake in Harmony Biosciences by 18.0% during the 4th quarter. Rhumbline Advisers now owns 108,588 shares of the company's stock valued at $3,736,000 after purchasing an additional 16,537 shares in the last quarter. New York State Teachers Retirement System lifted its stake in shares of Harmony Biosciences by 2.6% during the fourth quarter. New York State Teachers Retirement System now owns 31,693 shares of the company's stock worth $1,091,000 after buying an additional 809 shares during the period. Legato Capital Management LLC raised its stake in Harmony Biosciences by 26.0% in the 4th quarter. Legato Capital Management LLC now owns 26,720 shares of the company's stock worth $919,000 after acquiring an additional 5,506 shares during the last quarter. Finally, Louisiana State Employees Retirement System increased its holdings in Harmony Biosciences by 26.7% in the 4th quarter. Louisiana State Employees Retirement System now owns 18,500 shares of the company's stock worth $637,000 after buying an additional 3,900 shares during the period. Hedge funds and other institutional investors own 86.23% of the company's stock.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.